Regeneron Pharmaceuticals, Inc. (REGN) fair value analysis
S&P 500 · Updated 2026-10-19
REGN price how computed
Forward Fair Value verdict
Fairly valuedREGN is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $746.54
- Sector
- Healthcare
- 12-month range
- $577.95–$852.03
- Market cap
- $75.5B
- From 52-week high
- -12.4%
- Shares outstanding
- 101M
- Rank in Healthcare by discount to fair value
- #46 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, and commercializes medicines for serious medical conditions in areas including oncology, immunology, cardiovascular disease, and ophthalmology. The company operates globally with research, manufacturing, and commercial operations across the United States and international markets.
REGN currently ranks #46 of 108 Healthcare stocks by discount to fair value. It has screened as Fairly valued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $75.5B
- P/E (trailing)
- 16x
- Revenue (TTM)
- $15.5B
- Net margin
- 27.9%
- EPS (TTM)
- $45.27
- Gross margin
- 86.6%
- Debt / equity
- 0.06
- Revenue growth (3-yr avg)
- 9.2%
- Shares outstanding
- 101M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Stable
- 52-week position
- The upper-middle quarter of its range
- DCF cross-check
- Fairly Valued
Technicals how computed
- RSI (14-day)
- 54 · neutral
- 50-day average
- $790.85
- 200-day average
- $735.42
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Dividends how computed
- Paid, last 12 months
- $3.70 per share (4 payments)
- Yield on last price
- 0.50%
- Consecutive years of increases
- 0 (no streak on complete calendar years)
- Last ex-dividend date
- 2026-08-18
- Last payment date
- 2026-08-31
Earnings how computed
- Next earnings report
- 2026-10-30 (pre-market)
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+56.6%)
2026-03 ▲ beat (+6.4%)
2025-12 ▲ beat (+6.4%)
2025-09 ▲ beat (+22.7%)
2025-06 ▲ beat (+52.7%)
2025-03 ▼ miss (-3.1%)
2024-12 ▲ beat (+7.9%)
2024-09 ▲ beat (+6.5%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 17 buy · 9 hold · 1 sell (27 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $864
- Target vs last price
- +15.7%
What our data shows for REGN
- Our model validated 17 trailing price-to-earnings windows for REGN, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $577.95–$852.03.
- The 14-day relative strength index sits at a neutral 54.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for REGN
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent REGN news
TickrTrends' derived news-sentiment signal for REGN is currently leaning positive, computed from recent coverage.
- REGN Maintained by TD Cowen -- Price Target Raised to $980 (gurufocus.com, 2026-10-21)
TickrTrends take: TD Cowen's decision to raise REGN's price target to $980 while maintaining its rating suggests the analyst sees limited upside from current levels, which aligns with TickrTrends' assessment that the stock is fairly valued. For investors focused on valuation metrics, this maintenance rating indicates that while the company's fundamentals may have improved enough to warrant a higher target price, the stock's current trading price already reflects reasonable expectations for the Healthcare sector company. The gap between the raised target and current market pricing would be the key metric to monitor for whether REGN remains fairly valued or becomes attractive based on fundamental developments. - Novartis receives European Commission approval for Cosentyx® in polymyalgia rheumatica (PMR) (manilatimes.net, 2026-10-21)
TickrTrends take: Novartis's European Commission approval for Cosentyx in polymyalgia rheumatica represents a label expansion for an existing drug into a new indication, which could contribute incremental revenue to the company's immunology portfolio. For investors focused on REGN's valuation, competitive dynamics in the immunology and rheumatology space warrant monitoring, as approvals by competitors may influence market share and pricing pressures in segments where both companies operate. TickrTrends currently assesses REGN as fairly valued within the Healthcare sector, suggesting the market has already factored in known competitive and pipeline considerations. - REGN Maintained by Piper Sandler -- Price Target Raised to $865 (gurufocus.com, 2026-10-19)
TickrTrends take: Piper Sandler's price target increase to $865 for Regeneron Pharmaceuticals occurs within a context where TickrTrends currently assesses the company as fairly valued in the Healthcare sector. This analyst action suggests confidence in REGN's prospects, though the fairly valued designation indicates the market may already be pricing in meaningful growth expectations. Investors focused on valuation metrics should monitor whether upcoming results or pipeline developments alter the current equilibrium between stock price and intrinsic value.
More REGN news
- UBS Upgrades Regeneron Pharmaceuticals (REGN) on Next-Gen Dupixent Potential (gurufocus.com, 2026-10-14)
- Regeneron (REGN) Reports Positive 84-Week OPTIMA Trial Results for Pasatru in FOP Patients (gurufocus.com, 2026-10-12)
- Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension (manilatimes.net, 2026-10-12)
- Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets (insidermonkey.com, 2026-10-03)
What people are saying
Follow the REGN conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — REGN's relative valuation position improved this week as its sector discount rank moved from 65th to 56th among Healthcare companies, indicating it is trading at a more favorable valuation relative to its peers. The stock's valuation verdict shifted from Fairly valued to Undervalued, reflecting a strengthening assessment of its value proposition within the Healthcare sector.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is REGN stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), REGN is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is REGN's TickrTrends verdict?
REGN's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does REGN compare to other Healthcare stocks?
REGN ranks #46 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is REGN overbought or oversold?
REGN's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does REGN pay a dividend?
Yes. REGN paid $3.70 per share over the last twelve months (4 payments), a 0.50% yield on TickrTrends' last price. The last ex-dividend date was 2026-08-18.
When does REGN report earnings next?
REGN's next earnings report is scheduled for 2026-10-30 (pre-market), per the published earnings calendar.
Does REGN usually beat earnings estimates?
Over its last 8 reported quarters REGN beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about REGN?
Of 27 analysts covering REGN, 17 rate it a buy, 9 a hold and 1 a sell - buy-leaning, with a consensus price target of $864 (+15.7% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
REGN vs ENSG · REGN vs EXEL · REGN vs HCSG · REGN vs HSIC · REGN vs INVA